To elucidate the mechanisms underlying MIB1’s pro‐tumorigenic effects in pancreatic cancer, we performed immunoprecipitation and mass spectrometry to identify binding partners of MIB1 (Fig. S1A,B, and Table S3). The gene discussed is MIB1; the disease is pancreatic neoplasm.